Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (July 2012)
24 slides from Paratek Pharmaceuticals's investor presentation, Jul 11, 2012
Slide 1: Transcept Pharmaceuticals corporate presentation, July 2012
Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience July 2012
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectat
Slide 3: Transcept corporate overview
Transcept corporate overview Therapeutic focus Neuroscience / psychiatry Intermezzo: first FDA approval for middle of the Large markets, night awakening unmet needs TO-2061 : treatment resistant OCD, Ph2 data Q1-13 Commercial U.S. primary care partnership: Purdue Pharma platform Option to co-promote
Slide 4: Key strategic goals
Key strategic goals Work with Purdue to maximize Intermezzo adoption In-license or acquire marketed and/or late-stage products that complement psychiatry focus Begin next phase of TO-2061 development assuming successful completion of Phase 2 trial in Q1 2013 Build specialty sales/marketing capabilit
Slide 5: Intermezzo: national product launch April 2012
Intermezzo: national product launch April 2012 5
Slide 6: Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing Indication statement as approved by FDA: – Intermezzo is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. – Interm
Slide 7: Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing 7
Slide 8: Middle of the night awakening: a major unmet medical need in the insomnia category
Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category Large U.S. insomnia market – 79 million new and refill prescriptions(1) Insomnia is an under-treated condition(2) – 11 million patients receive Rx(3) – 4x to 6x more are not diagnosed or treated by a physician
Slide 9: Commonly prescribed sleep aids are indicated only for bedtime use
Commonly prescribed sleep aids are indicated only for bedtime use MOTN awakenings typically do not occur every night 7-8 hr sleep aids (Ambien® , Ambien CR®, Lunesta®) require bedtime prophylactic dosing to prevent awakenings An ideal therapeutic would: – Be used only at the time patients need help
Slide 10: Intermezzo: the first and only sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only sleep aid approved for middle-of-the night dosing Novel zolpidem formulation – Sublingual tablet – Bicarbonate-carbonate buffers Approved dose – 1.75 mg in women & patients > 65 years – 3.5 mg in men < 65 years Rapidly absorbed in both men and women Effective vs. place
Slide 11: Purdue Pharma: Intermezzo launch underway
Purdue Pharma: Intermezzo launch underway Purdue plans to invest ~$100M during first 12 months of Intermezzo launch ~275 field representatives in new national sales force devoted exclusively to the promotion of Intermezzo to highest insomnia prescribers Presentations to drug wholesaler, retailer and
Slide 12: Purdue commercialization agreement: key Transcept benefits
Purdue commercialization agreement: key Transcept benefits Remaining potential milestone payments – $10M when patent app. 11/439,874 is issued & published in Orange Book – Up to $70M upon the achievement of certain net sales targets Base royalty – Base royalty: mid-teens up to mid 20% level on net s
Slide 13: Intermezzo weekly Rx
Intermezzo weekly Rx Source: Wolters Kluwer Pharmaceutical Audit Suite 13
Slide 14: Intermezzo launch update
Intermezzo launch update Substantial managed care coverage achieved Improvement in adoption curve expected over time – Newly hired sales force calling on new physician targets – Physician audience unaccustomed to differentiating middle of the night insomnia • Requires a different interaction with th
Slide 15: Intermezzo: intellectual property
Intermezzo: intellectual property
Slide 16: Intermezzo patent protection
Intermezzo patent protection Two issued U.S. patents: 7,682,628 and 7,658,945 – Buffered dosage forms – Claims require absorption of zolpidem across the oral mucosa – Patent coverage through at least 2025 Notice of allowance: July 2012 – Methods of treating middle of the night insomnia No. 11/439,87
Slide 17: TO-2061 (low dose ondansetron)
TO-2061 (low dose ondansetron) Proposed indication: adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication 17
Slide 18: Significant unmet medical need: OCD patients not responding adequately to approved medication
Significant unmet medical need: OCD patients not responding adequately to approved medication Obsessive Compulsive Disorder – Intrusive thoughts and repetitive actions to reduce distress – Affects 1% to 2% of U.S. adult population, 40% to 50% seek treatment – Significantly impacts everyday life acti
Slide 19: Pilot Study: patients showed mean 26% improvement at 12 wks on the Yale Brown scale
Pilot Study: patients showed mean 26% improvement at 12 wks on the Yale Brown Obsessive Compulsive Disorder Scale Pilot Study, n=21 All Patients: n=21 Responders: n=12 of 21 (57%) 26.4% improvement at 12 weeks 44.0% improvement at 12 weeks 19
Slide 20: TO-2061: development overview
TO-2061 : development overview 505b2 NDA pathway Phase 2 double blind, placebo controlled study, n 150, complete enrollment est. Fall 2012, top line data est. Q1 2013 Intellectual property – Method of use patent application filed, priority date May 19, 2009 – Ondansetron, up to ~1.5 mg/day – Pending
Slide 21: Financial overview
Financial overview Transcept PHARMACEUTICALS. ING.
Slide 22: Financial position
Financial position 3/31/2012 Cash, equivalents & investments: $59 M 5/1/2012 update Net proceeds from public offering: $38 M Shares outstanding 19 M Options / warrants / other: 3M Total: 22 M Employees: 18 22
Slide 23: Key investment highlights
Key investment highlights Intermezzo launched April 2012 – First approval for middle of the night awakening – Large potential market – Significant royalty and co-promote opportunities – Increasing patent protection TO-2061 Phase 2 OCD data Q1 2013 Strong balance sheet 23
Slide 24: Trademark notices
Intermezzo ® is a registered trademark of Purdue Pharmaceuticals L.P. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta ® is a registered trademark of Sunovion Pharmaceuticals Inc. Paxil ® is a registered trademark of The GlaxoSmithKline Group of Companies Prozac ® is a re
Transcept Pharmaceuticals — Investor Presentation (July 2012) on 6ix